Sung Min Park, PhD

Clinical Pharmacology Modeling and Simulation, Allucent

Disclosure(s): TenNor Therapeutics (Suzhou) Ltd: Pharmacological statistician

Poster(s):

• (P-1064) Safety, Tolerability, and Pharmacokinetics of Rifaquizone for Injection in Healthy Participants in China: A Single-center, Double-blind, Randomized, Placebo-controlled, Phase 1 Bridge Study
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT